Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 - Seite 2

“More importantly, almost all treated patients developed a specific immune response against the antigen targets we selected, providing robust proof of principle for our lead candidate. TG4050 is now starting to show a potential benefit for head and neck cancer patients at high risk of relapse. We look forward to starting the Phase II part of the trial in the adjuvant setting for head and neck cancer.”

Dr. Oliver Lantz, Head of the clinical immunology laboratory at Institut Curie, added: “The immunological data generated by TG4050 demonstrate a robust and specific cellular immune response, even under stringent measurement criteria. The diversity, depth and duration of these responses were most certainly a key factor in preventing relapse in the patients treated with TG4050.”

Masamitsu Kitase, Corporate SVP and Head of the Healthcare and Life Sciences Division at NEC, concluded: “Our state-of-the-art proprietary artificial intelligence and machine learning models have allowed us to identify immunogenic and clinically relevant mutations in all head and neck cancer patients for this TG4050 randomized Phase I trial. These tumors were characterized by a low tumor mutation burden, which presents an obstacle to designing a relevant vaccine. Our powerful platform enables us to identify mutations for individualized treatments which have now shown the first signs of clinical benefit for patients. Together with Transgene, we look forward to continuing to build on these promising data through our planned Phase II trial in the adjuvant treatment of head and neck cancer.”    

TG4050 is being evaluated in a randomized multicenter Phase I/II trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166). Based on promising data obtained in the Phase I part of the trial, Transgene and NEC are preparing a randomized Phase II extension of this trial slated to start in the second quarter of 2024.

The poster can be viewed in-person during the poster presentation at the AACR 2024 meeting and accessed on Transgene’s website.

***

Contacts

Transgene: Lucie Larguier Chief Financial Officer [phone] [e-mail]	Media: MEDiSTRAVA Consulting  Frazer Hall/Sylvie Berrebi [phone] [e-mail]